PMID- 36531034
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221222
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Immune-based treatment re-challenge in renal cell carcinoma: A systematic review 
      and meta-analysis.
PG  - 996553
LID - 10.3389/fonc.2022.996553 [doi]
LID - 996553
AB  - INTRODUCTION: The use of immune checkpoint inhibitors (ICIs) as a front-line 
      treatment for metastatic renal cell carcinoma (RCC) has significantly improved 
      patient' outcome. However, little is known about the efficacy or lack thereof of 
      immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTLA monoclonal 
      antibodies. METHODS: Electronic databases, including PubMed, EMBASE, Medline, Web 
      of Science, and Cochrane Library, were comprehensively searched from inception to 
      July 2022. Objective response rates (ORR), progression-free survival (PFS), and >/= 
      grade 3 adverse events (AEs) were assessed in the meta-analysis, along with 
      corresponding 95% confidence intervals (CIs) and publication bias. RESULTS: Ten 
      studies which contained a total of 500 patients were included. The pooled ORR was 
      19% (95% CI: 10, 31), and PFS was 5.6 months (95% CI: 4.1, 7.8). There were >/= 
      grade 3 AEs noted in 25% of patients (95% CI: 14, 37). CONCLUSION: This 
      meta-analysis on different second-line ICI-containing therapies in ICI-pretreated 
      mRCC patients supports a modest efficacy and tolerable toxicity.
CI  - Copyright (c) 2022 Papathanassiou, Tamposis, Exarchou-Kouveli, Kontou, de Paz, 
      Mitrakas, Samara, Bagos, Tzortzis and Vlachostergios.
FAU - Papathanassiou, Maria
AU  - Papathanassiou M
AD  - Department of Pathology, Faculty of Medicine, School of Health Sciences, 
      University of Thessaly, Larissa, Greece.
FAU - Tamposis, Ioannis
AU  - Tamposis I
AD  - Department of Computer Science and Biomedical Informatics, University of 
      Thessaly, Lamia, Greece.
FAU - Exarchou-Kouveli, Kalliopi K
AU  - Exarchou-Kouveli KK
AD  - Department of Computer Science and Biomedical Informatics, University of 
      Thessaly, Lamia, Greece.
FAU - Kontou, Panagiota I
AU  - Kontou PI
AD  - Department of Mathematics, University of Thessaly, Lamia, Greece.
FAU - de Paz, Anna Tzortzi
AU  - de Paz AT
AD  - Department of Urology, Faculty of Medicine, School of Health Sciences, University 
      of Thessaly, University Hospital of Larissa, Larissa, Greece.
FAU - Mitrakas, Lampros
AU  - Mitrakas L
AD  - Department of Urology, Faculty of Medicine, School of Health Sciences, University 
      of Thessaly, University Hospital of Larissa, Larissa, Greece.
FAU - Samara, Maria
AU  - Samara M
AD  - Department of Pathology, Faculty of Medicine, School of Health Sciences, 
      University of Thessaly, Larissa, Greece.
FAU - Bagos, Pantelis G
AU  - Bagos PG
AD  - Department of Computer Science and Biomedical Informatics, University of 
      Thessaly, Lamia, Greece.
FAU - Tzortzis, Vassilios
AU  - Tzortzis V
AD  - Department of Urology, Faculty of Medicine, School of Health Sciences, University 
      of Thessaly, University Hospital of Larissa, Larissa, Greece.
FAU - Vlachostergios, Panagiotis J
AU  - Vlachostergios PJ
AD  - Department of Medicine, Division of Hematology and Medical Oncology, Weill 
      Cornell Medicine, New York, NY, United States.
LA  - eng
PT  - Systematic Review
DEP - 20221202
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9756433
OTO - NOTNLM
OT  - VEGF TKI
OT  - immune checkpoint inhibitor
OT  - immunotherapy
OT  - rechallenge
OT  - renal cell carcinoma
OT  - salvage
OT  - second-line
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/20 06:00
MHDA- 2022/12/20 06:01
PMCR- 2022/01/01
CRDT- 2022/12/19 03:43
PHST- 2022/07/17 00:00 [received]
PHST- 2022/10/31 00:00 [accepted]
PHST- 2022/12/19 03:43 [entrez]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/20 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.996553 [doi]
PST - epublish
SO  - Front Oncol. 2022 Dec 2;12:996553. doi: 10.3389/fonc.2022.996553. eCollection 
      2022.